These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Dendritic cells in cancer immunotherapy. Vulink A; Radford KJ; Melief C; Hart DN Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410 [TBL] [Abstract][Full Text] [Related]
63. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530 [TBL] [Abstract][Full Text] [Related]
64. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands. Raaijmakers TK; Ansems M Cancer Immunol Immunother; 2018 Nov; 67(11):1789-1796. PubMed ID: 29998375 [TBL] [Abstract][Full Text] [Related]
65. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Saxena M; Bhardwaj N Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962 [TBL] [Abstract][Full Text] [Related]
66. [Dendritic cell vaccines loaded with autologous tumor lysates for solid tumors]. Kamigaki T; Takahara M; Teruya T Nihon Rinsho; 2017 Feb; 75(2):288-294. PubMed ID: 30562866 [TBL] [Abstract][Full Text] [Related]
67. Engineering dendritic cells to enhance cancer immunotherapy. Boudreau JE; Bonehill A; Thielemans K; Wan Y Mol Ther; 2011 May; 19(5):841-53. PubMed ID: 21468005 [TBL] [Abstract][Full Text] [Related]
68. Strategies for improved antigen delivery into dendritic cells. Rea D; Johnson ME; Havenga MJ; Melief CJ; Offringa R Trends Mol Med; 2001 Mar; 7(3):91-4. PubMed ID: 11286763 [TBL] [Abstract][Full Text] [Related]
73. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Qian D; Li J; Huang M; Cui Q; Liu X; Sun K Biomed Pharmacother; 2023 Jun; 162():114685. PubMed ID: 37058818 [TBL] [Abstract][Full Text] [Related]
74. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Elster JD; Krishnadas DK; Lucas KG Hum Vaccin Immunother; 2016 Sep; 12(9):2232-9. PubMed ID: 27245943 [TBL] [Abstract][Full Text] [Related]
75. Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality. Coughlin CM; Vonderheide RH Cancer Biol Ther; 2003; 2(5):466-70. PubMed ID: 14614310 [TBL] [Abstract][Full Text] [Related]
76. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Saadeldin MK; Abdel-Aziz AK; Abdellatif A Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134 [TBL] [Abstract][Full Text] [Related]
77. A proposal for a simple and inexpensive therapeutic cancer vaccine. Fahrer AM Immunol Cell Biol; 2012 Mar; 90(3):310-3. PubMed ID: 21606943 [TBL] [Abstract][Full Text] [Related]
78. New technologies toward dendritic cell-based cancer immunotherapies. Matsue H; Morita A; Matsue K; Takashima A J Dermatol; 1999 Nov; 26(11):757-63. PubMed ID: 10635619 [TBL] [Abstract][Full Text] [Related]
79. Antigen delivery to plasmacytoid dendritic cells -induction of tolerance and immunity. Loschko J; Krug A Crit Rev Immunol; 2012; 32(6):489-501. PubMed ID: 23428225 [TBL] [Abstract][Full Text] [Related]
80. Regulatory dendritic cells: new targets for cancer immunotherapy. Shurin MR; Naiditch H; Zhong H; Shurin GV Cancer Biol Ther; 2011 Jun; 11(11):988-92. PubMed ID: 21474998 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]